Explorer les evidences

90 %From 1st July 2022 to 30th June 2023, 90% of women with visual inspection with acetic acid (VIA) positive lesions received appropriate treatment.

Kenyacancer du col de l'utérusobservé 1st July 2022 to 30th June 2023publié 2025BMC women's healthPubMeddocument de 8 observations

49,7 %Ever-screening for cervical cancer was reported by 49.7% of the 736 Kenyan respondents.

Kenyacancer du col de l'utérusobservé 2022-2023publié 2025BMC public healthPubMeddocument de 8 observations

100 %Squamous cell carcinoma was present in 100% of people living with HIV and 88.0% of HIV-negative patients.

Kenyacancer du col de l'utérusobservé 2014–2023publié 2026BMC cancerPubMeddocument de 16 observations

24 %24% of women aged ≥25 years attending infant immunization clinics in Kenya reported a history of cervical cancer screening.

Kenyacancer du col de l'utérusobservé 2018 and 2019publié 2025BMC women's healthPubMeddocument de 8 observations

57 %The 1 and 2-year survival probability after diagnosis of cervical cancer was 57% and 45% respectively.

Kenyacancer du col de l'utéruspublié 2023BMC cancerPubMeddocument de 12 observations

28 %Clinics that did not report cervical cancer screening had 28% (9/32) with at least one provider trained to perform cervical cancer screening.

Kenyacancer du col de l'utérusobservé 2017-2018publié 2022BMC health services researcheurope_pmcdocument de 10 observationsDOI 10.1186/s12913-022-08984-2

49 %The largest share of guideline-adherent cancer-directed therapy was observed in Nairobi (49%).

Kenyacancer du col de l'utéruspublié 2021The oncologisteurope_pmcdocument de 14 observationsDOI 10.1002/onco.13718

13,8 %In Kenya, only 13.8% of women participate in cervical cancer screening programs.

Kenyacancer du col de l'utéruspublié 2026BMC research notesPubMeddocument de 7 observations

16,3 %Cervical cancer screening was reported in 16.3% of HIV-uninfected women attending infant immunization clinics in Kenya.

Kenyacancer du col de l'utérusobservé 2018 and 2019publié 2025BMC women's healthPubMeddocument de 8 observations

70 %HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases.

Kenyacancer du col de l'utéruspublié 2022Frontiers in public healthPubMeddocument de 4 observations

87 %Only 87% (33) of clinics that reported performing cervical cancer screening had dependable access to speculums.

Kenyacancer du col de l'utérusobservé 2017-2018publié 2022BMC health services researcheurope_pmcdocument de 10 observationsDOI 10.1186/s12913-022-08984-2

9 000 casesAnnual vaccine supply disruptions would avert less than 9,000 cervical cancer cases compared with a 1-dose strategy.

Kenyacancer du col de l'utérusPubMeddocument de 6 observations

45,3 %During a national phone survey in Kenya, 45.3% of male respondents had discussed cervical cancer with their wife/partner.

Kenyacancer du col de l'utéruspublié 2026Cancer epidemiology, biomarkers & prevention : a publication of the American Association fPubMeddocument de 5 observations

40 %Lymphovascular space invasion (LVSI) was the predominant intermediate-risk feature, occurring in 40.0% of HIV-negative patients.

Kenyacancer du col de l'utérusobservé 2014–2023publié 2026BMC cancerPubMeddocument de 16 observations

16 %The proportion of HIV-infected women screened for cervical cancer increased from 16% to 57% in the intervention arm after the nurse-led health education intervention.

Kenyacancer du col de l'utéruspublié 2025Asian Pacific journal of cancer prevention : APJCPPubMeddocument de 5 observations

Cervical cancer is the second most common cancer after breast cancer among women in Kenya.

Kenyacancer du col de l'utéruspublié 2023BMC cancerPubMeddocument de 12 observations

48 %Among women attending large HIV care and treatment programs across Kenya between June and September 2016, 804 (48%) of those who reported ever being screened were screened within the last 12 months.

Kenyacancer du col de l'utérusobservé June and September 2016publié 2022International journal of gynaecology and obstetrics: the official organ of the InternationPubMeddocument de 3 observations

16 %In Kenya, the estimated cervical cancer screening uptake among women aged 30–49 is 16%.

Kenyacancer du col de l'utéruspublié 2023Implementation science : ISPubMeddocument de 2 observations

17 %The cervical cancer screening rate in Kenya currently stands at 16-18%.

Kenyacancer du col de l'utéruspublié 2024BMC women's healthPubMeddocument de 3 observations

16 000 casesA gradual scale-up of the current 2-dose quadrivalent vaccine (4vHPV) program would avert an additional 16,000 cervical cancer cases compared with maintaining current program performance.

Kenyacancer du col de l'utérusPubMeddocument de 6 observations

173 000 casesCompared with no vaccination, maintaining current program performance would avert approximately 173,000 cervical cancer cases across 2019 to 2100.

Kenyacancer du col de l'utérusobservé 2019 to 2100PubMeddocument de 6 observations

10,8 %Across the 19 facilities, 10.8% of the women enrolled in care at the hospital were screened for cervical cancer during the data collection period.

Kenyacancer du col de l'utérusobservé September 2021 to September 2022publié 2025JCO global oncologyPubMeddocument de 3 observations

34,8 %Thirty-four point eight percent (34.8%) of the respondents obtained information about cervical cancer from health talks.

Kenyacancer du col de l'utéruspublié 2016Journals & Books Hosting (International Knowledge Sharing Platform)OpenAlexdocument de 18 observations

69,2 %Lymphovascular space invasion (LVSI) was the predominant intermediate-risk feature, occurring in 69.2% of people living with HIV and 40.0% of HIV-negative patients.

Kenyacancer du col de l'utérusobservé 2014–2023publié 2026BMC cancerPubMeddocument de 16 observations

2,5 %Mauritius had a constant annual 2.5% decline in cervical cancer incidence.

Kenyacancer du col de l'utéruspublié 2020British journal of cancereurope_pmcdocument de 5 observations